Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Data up to Jan 2025
Total Citations Per Year
Abstract
References (17)
Diseases of the Breast
1971 • 1,803 citations
The urokinase-type plasminogen activator system in cancer metastasis: A review
1997 • 1,561 citations
Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
1996 • 749 citations
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
1995 • 711 citations
Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients
2002 • 592 citations
Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1
2001 • 442 citations
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
2000 • 414 citations
Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy
1997 • 391 citations
Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer
1993 • 367 citations
Urokinase plasminogen activator: A prognostic marker in multiple types of cancer
1999 • 199 citations
Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer
1995 • 161 citations
The role of HER-2 expression in predicting response to therapy in breast cancer.
2000 • 95 citations
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up
1999 • 91 citations
Invasion marker PAI‐1 remains a strong prognostic factor after long‐term follow‐up both for primary breast cancer and following first relapse
1999 • 90 citations
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours
2001 • 68 citations
Clinical relevance of the urokinase plasminogen activator system in breast cancer
1999 • 64 citations
Modulators of the urokinase-type plasminogen activation system for cancer
2000 • 11 citations